Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | MST1R | Q04912 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | ROS1 | P08922 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334421 | 0.82 | KDR (0.54) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL1335484 | 0.82 | KDR (0.59) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL28223905 | 0.81 | CLK4 (0.56) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL30543362 | 0.77 | KDR (0.49) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL10049030 | 0.77 | BTK (0.46) | KDR | |
| SCHEMBL30915419 | 0.77 | KDR (0.49) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL1333209 | 0.76 | KDR (0.57) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL1078443 | 0.76 | CDK5 (0.61) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL29871952 | 0.76 | CDK5 (0.61) | KDRPIK3CDPIK3CBPIK3CACLK4 | |
| SCHEMBL1335395 | 0.75 | PIK3CD (0.56) | KDRPIK3CDPIK3CBPIK3CACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | disclosed |
| US-7129260-B2 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287370-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885PIK3CD 190/4885PIK3CB 119/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885PIK3CD 190/4885PIK3CB 119/4885 |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABL1, LCK, MAP3K7 | KDR 527/4885PIK3CD 190/4885PIK3CB 119/4885 |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | MAP3K7, MAP3K5, MAP3K20 | KDR 909/4885PIK3CD 193/4885PIK3CB 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.